Prostacyclin pathway vasodilators in patients with chronic thromboembolic pulmonary hypertension (CTEPH): A systemic review and meta-analysis of randomized controlled trials.

Pulm Circ · 2024 · PMC11483533 · PMID 39421016

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

an observed trendno p-value reported

PVR, mRAP, cardiac index, and WHO functional class were significantly improved in CTEPH patients treated with the prostacyclin pathway vasodilators compared to the controls, additionally, there was an observed trend towards improvement in mPAP, 6MWD, and NT‐proBNP.

also in 242 other papers

showed a trendno p-value reported

Mean pulmonary arterial pressure The mPAP was reported in four studies, 6 , 16 , 18 , 19 which showed a trend improvement in the prostacyclin pathway vasodilator treatment compared to controls.

also in 22,539 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.